Pfizer
NEWS
MorphoSys U.S. Inc., Pfizer and Incyte are teaming up to test Pfizer’s TTI-622 in conjunction with Monjuvi plus lenalidomide in patients with lymphoma.
While a handful of companies have dominated the COVID-19 vaccine market in the U.S. and Europe, a number of biotechs are continuing to develop vaccines to use as booster shots.
GSK reported positive headline data from a pre-specified efficacy interim analysis of the Phase III trial of its RSV vaccine.
The FDA plans to review changes to Novavax’s manufacturing process before it authorizes its vaccine.
On Tuesday, the FDA’s Vaccines and Related Biological Products Advisory Committee voted 21-0 with one abstention to recommend authorization of Novavax’s COVID-19 vaccine.
Ibrance, a first-line treatment for ER+, HER2 - metastatic breast cancer, did not improve the overall survival rate in patients. Read on to know more.
The FDA has expressed worries over four cases of heart inflammation, or myocarditis, that were observed in pivotal clinical trials of Novavax’s COVID-19 vaccine.
Pfizer’s Paxlovid shows benefits for vaccinated and unvaccinated patients for COVID-19, ages 65 and up while the White House indicates children under five could receive COVID vaccines by June 21.
June is starting off with a number of important dates for the FDA, including an advisory committee meeting to discuss COVID-19 vaccines in children as young as six months.
JOBS
IN THE PRESS